Nutex Health (NASDAQ:NUTX) Lowered to "Buy" Rating by Wall Street Zen

Key Points

• Nutex Health (NASDAQ:NUTX) has been downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen.
• Maxim Group has set a price target of $205.00 for NUTX shares, while the consensus target price is $252.50.
• Institutional investors have increased their positions significantly, with Topline Capital Management boosting its stake by 72.0% in the second quarter.

Nutex Health (NASDAQ:NUTX - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.

Several other brokerages have also commented on NUTX. Maxim Group set a $205.00 price target on shares of Nutex Health and gave the stock a "buy" rating in a research report on Tuesday, August 26th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Nutex Health in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $252.50.

Nutex Health Stock Performance

Shares of NUTX stock opened at $94.83 on Friday. Nutex Health has a one year low of $21.45 and a one year high of $184.27. The company has a debt-to-equity ratio of 1.02, a quick ratio of 2.26 and a current ratio of 2.27. The company has a 50 day moving average price of $95.44 and a 200 day moving average price of $112.86. The firm has a market capitalization of $526.78 million, a price-to-earnings ratio of 7.98 and a beta of -0.20.

Institutional Investors Weigh In On Nutex Health

Several large investors have recently made changes to their positions in NUTX. Topline Capital Management LLC increased its position in shares of Nutex Health by 72.0% in the second quarter. Topline Capital Management LLC now owns 309,131 shares of the company's stock worth $38,484,000 after acquiring an additional 129,418 shares in the last quarter. Marshall Wace LLP increased its position in shares of Nutex Health by 333.4% in the second quarter. Marshall Wace LLP now owns 94,548 shares of the company's stock worth $11,770,000 after acquiring an additional 72,734 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in shares of Nutex Health in the second quarter worth $7,481,000. Geode Capital Management LLC boosted its stake in shares of Nutex Health by 116.8% in the second quarter. Geode Capital Management LLC now owns 78,859 shares of the company's stock valued at $9,819,000 after purchasing an additional 42,484 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in shares of Nutex Health in the third quarter valued at $3,299,000. Institutional investors and hedge funds own 5.32% of the company's stock.

Nutex Health Company Profile

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.